Influence of Biological Therapeutics, Cytokines, and Disease Activity on Depression in Rheumatoid Arthritis

Table 5

Correlations between depressive symptoms and SLE clinical assessments.

	SLE subjects
	()	Pseudo ^2	AICc	Coefficient	Odds ratio (95% CI)	value
Characteristics
Disease duration (years), mean ± SD	17.81 ± 8.85	0.021	467.95	0.006	1.01 (1.00-1.02)	0.211
BMI, mean ± SD	24.51 ± 5.60	0.103	461.59	0.021	1.02 (1.01–1.03)	0.003
Smoking, number (%)
Yes	13 (18)	0.032	467.14	−0.186	0.83 (0.65–1.05)	0.133
Drinking, number (%)
Yes	7 (10)	0.006	469.03	0.100	1.11 (0.82–1.45)	0.489
Physical activity, number (%)
Yes	24 (33)	0.054	465.43	−0.196	0.82 (0.68–0.99)	0.047
Laboratory
Sedimentation velocity, mean ± SD	23.48 ± 20.96	0.355	440.12	0.003	1.00 (1.00-1.01)	0.220
C-reactive protein, mean ± SD	0.44 ± 0.57	0.191	454.67	0.120	1.13 (0.97–1.29)	0.094
Leukocytes, mean ± SD	6.73 ± 2.13	0.160	457.26	−0.003	1.00 (0.96–1.04)	0.884
Brain leukocytes, mean ± SD	6.22 ± 2.20	1.000	91.44	0.121	1.13 (1.04–1.23)	0.005
Lymphocytes, mean ± SD	28.89 ± 8.09	0.160	457.27	0.001	1.00 (0.99–1.01)	0.929
Brain lymphocytes, mean ± SD	29.05 ± 6.77	1.000	96.64	−0.022	0.98 (0.95–1.01)	0.117
Anti-dsDNA, mean ± SD	98.79 ± 111.01	0.829	370.64	< 0.001	1.00 (1.00-1.00)	0.990
Brain anti-dsDNA, mean ± SD	635.54 ± 1504.14	1.000	96.28	< 0.001	1.00 (1.00-1.00)	0.081